Literature DB >> 30526033

Novel non-nucleotidic STING agonists for cancer immunotherapy.

Gilles Berger1, Sean E Lawler2.   

Abstract

Entities:  

Keywords:  STING; cancer immunotherapy; cyclic dinucleotides

Mesh：

Substances：

Year:  2018        PMID： 30526033     DOI： 10.4155/fmc-2018-0367

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  3 in total

Review 1.  STING pathway agonism as a cancer therapeutic.

Authors:  Blake A Flood; Emily F Higgs; Shuyin Li; Jason J Luke; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

2.  STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.

Authors:  Carminia M Della Corte; Triparna Sen; Carl M Gay; Kavya Ramkumar; Lixia Diao; Robert J Cardnell; Bertha Leticia Rodriguez; C Allison Stewart; Vassiliki A Papadimitrakopoulou; Laura Gibson; Jared J Fradette; Qi Wang; Youhong Fan; David H Peng; Marcelo V Negrao; Ignacio I Wistuba; Junya Fujimoto; Luisa M Solis Soto; Carmen Behrens; Ferdinandos Skoulidis; John V Heymach; Jing Wang; Don L Gibbons; Lauren A Byers
Journal:  J Thorac Oncol       Date:  2020-02-15       Impact factor: 15.609

Review 3.  STING: a master regulator in the cancer-immunity cycle.

Authors:  Yuanyuan Zhu; Xiang An; Xiao Zhang; Yu Qiao; Tongsen Zheng; Xiaobo Li
Journal:  Mol Cancer       Date:  2019-11-04       Impact factor: 27.401
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.